From TokenPost · · 50s
Xenon Begins Q1 2027 Azetukalner Study
Xenon Pharmaceuticals starts Phase 3b/4 trial for focal seizures in Q1 2027.
In brief
Xenon Pharmaceuticals starts Phase 3b/4 trial for focal seizures in Q1 2027. Xenon Pharmaceuticals plans to begin a Phase 3b/4 study of azetukalner for focal seizures in Q1 2027 after filing a new drug application in Q3 2026. Originally reported by TokenPost.
Xenon Pharmaceuticals
Xenon Pharmaceuticals plans to begin a Phase 3b/4 study of azetukalner in Q1 2027 as it pursues U.S. approval for focal seizures after filing a new drug application in Q3 2026.
Financial Position
Xenon ended Q3 with $1.2 billion in cash, cash equivalents and marketable securities. The company expects those resources to fund operations into 2029 under current plans.
X-NOVA2 Results
Xenon expects topline results from X-NOVA2, a study in major depressive disorder (MDD), in December 2026.
The big picture
Xenon Pharmaceuticals plans to begin a Phase 3b/4 study of azetukalner for focal seizures in Q1 2027 after filing a new drug application in Q3 2026.
